Did you lose money on investments in Unisys Corporation? Let’s talk about it! Calling all Unisys Corporation shareholders! Are you one of the unfortunate investors who lost money on investments in Unisys Corporation (NYSE: UIS)? If so, you may be entitled to compensation. Don’t suffer in silence – take action now by contacting Peter Allocco…
Welcome to the Wonderful World of Portillo’s! A Tasty Investment Opportunity Have you heard the news? Portillo’s Inc. is making waves in the fast-casual dining scene with its announcement of a public offering of Class A common stock. That’s right, you now have the chance to own a piece of this beloved Chicago-style favorite! What…
Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Monoclonal Antibodies BOGART, Georgia, Nov. 14, 2022 (GLOBE NEWSWIRE) — Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, Type 2 inflammatory diseases, and oncology, today announced that the United States Patent and Trademark Office has issued U.S. Patent…
GWG Holdings, Inc. Announces Resignations of Murray T. Holland as President and Chief Executive Officer and Timothy L. Evans as Chief Financial Officer and Treasurer DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) — GWG Holdings, Inc. (Nasdaq: GWGH) (the “Company”), a financial services firm based in Dallas, Texas, today announced that the Company’s President and Chief…
Are You Feeling Salty About Your Investments? Don’t Let Compass Minerals International, Inc. Leave You Feeling Bitter! Stay on Top of Your Game with Glancy Prongay & Murray LLP LOS ANGELES, Nov. 14, 2022 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 20, 2022 deadline to file a…
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results Achieving Clinical and Regulatory Milestones Longeveron Inc. has achieved key clinical and regulatory milestones across its clinical pipeline. One notable accomplishment is the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease. This milestone marks a significant step forward in the…
Welcome to the World of Palisade Bio! Financial Results and Business Update Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) Hey there, fellow health enthusiasts! Have you heard the latest news from Palisade Bio, Inc.? This innovative clinical stage biopharmaceutical company, traded as Nasdaq: PALI, is making waves in the world of gastrointestinal (GI) therapies. In…
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency Introduction Lumos Pharma recently reported positive interim results from two Phase 2 trials evaluating LUM-201, a potential breakthrough in the treatment of Pediatric Growth Hormone Deficiency (PGHD). The trials have shown promising growth in pediatric…
